RT Book, Section A1 Jenkins, Sasha A1 Cotes, Maren A1 Zwald, Fiona A2 Avram, Marc R. A2 Avram, Mathew M. A2 Ratner, Désirée SR Print(0) ID 1175094650 T1 Skin Cancer in the Organ Transplant Patient T2 Procedural Dermatology YR 2015 FD 2015 PB McGraw-Hill Education PP New York, NY SN 9780071795067 LK dermatology.mhmedical.com/content.aspx?aid=1175094650 RD 2024/10/09 AB Advances in the management of solid organ transplantation recipients (OTR) have led to improved overall survival. However, patients face many consequences of being on long-term immunosuppression, including an increased risk of developing premalignant and malignant skin cancers. This is likely to pose an increasing challenge to dermatologists, as the number of patients receiving a solid organ transplant continues to grow and the life expectancy of these patients continues to increase. Skin cancers are the most common malignancy posttransplantation, comprising almost 40% of posttransplant malignancies, and tend to behave more aggressively than in nontransplant patients.1 The increased risk of skin cancer impacts patient morbidity and quality of life post transplantation, and management of such cases places a significant burden on diminishing health care resources.